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Abstract
Background: Despite France being regarded as a model of efficient harm reduction policy and
equity of access to care in the general community, the health of French inmates is a critical issue,
as harm reduction measures are either inaccessible or only partially implemented in French prisons.
Method: Using specific inclusion and exclusion criteria, information was collected and analyzed
about HIV, HBV and HCV prevalence, risk practices, mortality, access to harm reduction measures
and care for French prison inmates.
Results: Data about the occurrence of bloodborne diseases, drug use and access to care in prisons
remain limited and need urgent updating. Needle exchange programs are not yet available in French
prisons and harm reduction interventions and access to OST remain limited or are heterogeneous
across prisons. The continuity of care at prison entry and after release remains problematic and
should be among the primary public health priorities for French prisoners.
Conclusion: Preventive and harm reduction measures should be urgently introduced at least as
pilot programs. The implementation of such measures, not yet available in French prisons, is not
only a human right for prison inmates but can also provide important public health benefits for the
general population.
Introduction
There is increasing acknowledgement that the health of
prison inmates is both a critical issue in its own right and
a public health concern, as after release inmates may dis-
continue HIV care or opioid substitution treatments and
be more inclined to engage in unsafe injecting practices.
The physical and mental health of persons entering prison
is often poor and may be further impaired after entry by a
combination of factors including high risk sexual and
drug injecting behavior [1-4], violence, non-consensual
sex [5] and mental illness [6-8].
Many inmates cycle in and out of prison repeatedly,
increasing the likelihood that any infections contracted in
prison could soon affect the general community. There-
fore, careful surveillance of infections in prison popula-
tions could help to predict future outbreaks of infections
in the general population [9,10].
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Moreover, in many countries in the world today, a consid-
erable percentage of people entering prison are drug
dependent prior to incarceration and many of these con-
tinue to use drugs, generally by injection, after entering
prison [11-15]. The major 'currencies' used in prisons
around the world are sex and drugs. It is very difficult for
prison authorities around the world to ever acknowledge
the fact that vigorous and expensive efforts to prevent
drugs from entering prison have very limited effect and
may render drug injection which does occur even more
hazardous. When needle exchange programs (NEP) are
unavailable in the prison setting, HIV-HCV risk behaviors
may be extremely frequent as documented by some stud-
ies reporting risk behaviors [1-4] and may result in HIV –
HCV seroconversions in the prison setting [11,16-19].
Injecting equipment used in prisons is excessively worn,
thereby increasing the risk of blood borne viral transmis-
sion. Equipment sharing generally occurs with many part-
ners from diverse geographical and social networks,
further increasing the potential public health impact.
Studies underestimate the extent of the problem as sero-
conversion often occurs after release although the infec-
tion occurred during the period of incarceration.
In addition, lack or difficult access to condoms also con-
tributes to an increased risk of HIV or HBV seroconversion
due to high risk sexual behaviors including sexual assault
[20], while frequent movements of inmates within the
prison system and the almost inevitable over-crowding of
prisons facilitate the spread of tuberculosis [21-26].
Despite the increasing interest in health in prisons, the
inadequate access to preventive measures and the lack of
an efficient and comprehensive system of care (including
care for psychiatric co-morbidities), make the need to
improve correctional health services and outcomes a mat-
ter of urgency.
In 1996 France was faced with an alarming HIV epidemic
among drug users. HIV prevalence among injecting drug
users was estimated to be 40% [27], forcing the adoption
of harm reduction including the scale up of NSPs (needle
syringe programs) and the introduction of opioid substi-
tution treatment (OST) – buprenorphine in primary care
and methadone, also available in primary care after dose
stabilization. Within 10 years, the benefits of this
approach were self-evident: a 5-fold reduction in overdose
deaths [28] and a four-fold reduction in HIV prevalence
(11%) in drug users [29]. The decrease in HCV prevalence
among drug users – from 70% to 60% – was less impres-
sive [29].
Despite the World Health Organization (WHO) state-
ment  "All prisoners have the right to receive health care,
including preventive measures, equivalent to that available in
the community"[30], NSPs and easy access to condoms are
not yet available in French prisons while access to and
varieties of available OST vary greatly from one prison to
another. The variability in prison OST is partly attributa-
ble to the specific health policy of some prisons but also
reflects the difficulties of employing adequate numbers
and assuring quality of staff.
Data from the French correctional system about drug use,
risk behaviors of inmates, HIV and HCV seroprevalence,
access to OST, antiretroviral treatment and post-exposure
prophylaxis is scattered throughout many different
reports or papers. Most are in French with only a few
papers in English and some of these are obsolete as they
pertain to the era before highly active antiretroviral treat-
ment (HAART).
The objective of this review is to summaries the health
data available regarding French prison inmates, to indi-
cate the need for future research to improve the health sta-
tus of prisoners and to encourage access to health care for
the inmate population equivalent to standards available
in the community.
Materials and methods
Criteria for considering studies for this review
Literature was reviewed starting from the most recent
reports and papers available on the internet as well as
those presented at French conferences dealing with HIV,
HCV, harm reduction, or prevention in French prisons.
Using the references cited in these papers and reports it
was possible to retrieve still other studies and reports
including those belonging to grey literature.
Once all the documents were accessible we used the fol-
lowing inclusion criteria: studies documenting HIV, HCV
and HBV; suicide rates; drug use and alcohol consump-
tion; HIV-HCV-HBV risk practices; access to HAART and
opioid substitution treatment and continuity of care both
during prison stay and after release; recidivism rates;
knowledge, attitudes and practices towards harm reduc-
tion measures such as NEP or condom distribution.
Though more related to psychiatric co-morbidities, sui-
cides were included in this review because of the link
between drug use and suicide risk. Data collected from
inmates or health care professionals working in prisons
were included in these studies.
Exclusion criteria excluded studies focusing on psychiatric
comorbidities and care or other conditions not directly
related to bloodborne transmission.
Moreover epidemiological studies whose methodology
for data collection remained undefined or inaccurate wereHarm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
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excluded from this review. Only data pertaining to the last
15 years were included in this review.
Results
As of January 1st 2006, 59,522 inmates were incarcerated
in French prisons. Among them, 19,732 (33.8%) were
awaiting sentence and 38,612 (66.2%) had already been
sentenced, 14.4% of those for drug related offences [31].
In 2005 [32], 36,264 had been sentenced for drug related
offences (23,760 prison terms including 8,334 imprison-
ments and 15,426 partial or total suspended sentences,
with or without probation), 12,564 for possession/acqui-
sition of drugs, 13,104 for illicit use, 1,943 for trafficking,
6,571 for trading/transport and 1,924 for offering drugs).
The mean duration of imprisonment for drug related
offences was 13.9 months (3.4 months for a single
offence, 15.3 months for multiple offences), 11.4 months
for acquisition and detention, 6.1 months for illicit drug
use, 27.9 months for trafficking (import, export), 15.7
months for trading/transport, and 9.5 months for offering
drugs.
Since 1994, health in French prisons has been the respon-
sibility of the Ministry of Health. Care provision for
inmates is organized in cooperation with neighborhood
hospitals independently from the prison administration.
Care is freely available with inmates getting full benefits
from social insurance from the time they enter prison.
After release, inmates (and their family) can still benefit
from free health care for four years. Costs of screening,
treatment and staff are included in the global budget of
the hospitals. Resources allocated to care for inmates in
need have been increased frequently, especially since
1994.
Health status at prison entry
HIV, HCV, HBV at prison entry
At entry to a French prison, all inmates must undergo a
comprehensive medical examination. The Ministry of
Health collected the available medical data from these
examinations in 1997 and 2003 for all prisons in France
[33]. The duration of data collection in 2003 varied
according to the size of the prison (2 weeks for a large
prison with 9,272 new inmates in 2002, 1 month for jails
with more than 600 entrants in 2002, 2 months for pris-
ons with between 300 and 600 entrants, 3 months for jails
with fewer than 300 entrants in 2002).
The proportion of inmates tested for HIV and HBV at
admission (see table 1) decreased from 1997 to 2003
(46.5% in 1997 vs. 40.0% in 2003 and 25% in 1997 vs.
20.5% in 2003 respectively), but increased for HCV
(19.7% in 1997, 27.4% in 2003). The proportion of
inmates vaccinated against HBV at entry increased from
13.7% in 1997 to 31.3% in 2003.
Prevalence of HIV at entry (self-reported) decreased from
1.6% in 1997 to 1.1% in 2003, with 0.8% vs. 0.5% report-
ing receiving HAART respectively.
Prevalence of HCV and HBV at entry (self-reported)
decreased respectively from 4.4% in 1997 to 4.2% in 2003
and 2.3% in 1997 to 0.8% in 2003.
HIV prevalence for inmates reporting a history of drug
injection decreased from 9% to 5% between 1997 and
2003 [33].
In a national postal survey of prison medical services for
HCV screening and care conducted in 2000 and again in
Table 1: Access to care and HIV, HBV and HCV status at prison entry and during prison stay.
Mouquet Mouquet Remy Remy Drassif
1997 (%) 2003 (%) 2000 (%) 2003 (%) 2005 (%)
135 prisons Incoming 
inmates*
134 prisons Incoming 
inmates*
85 prisons 27 245 
inmates**
88 prisons 31215 
inmates**
8 prisons Incoming 
inmates***
HCV positive test 4.4a 4.2a 6.3b 6.9b 5.9 b
% of inmates screened 20 27 ND ND 38
HBV positive test 2.3a 0.8a 3.4 b
% of inmates screened 25 20 37
HIV positive test 1.6a 1.1a 0.6 b
% of inmates screened 46 40 41
HAART at prison 
entry
0.8 0.5 1.4
HCV treatment (total 
number/1 year)
164 297 171
*study period : from 2 weeks to 3 months depending of the size of the prison
** cross-sectional study
***study period : 2005
aself-reported serostatus among those who reported to have had already been screened
b positive testHarm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
Page 4 of 11
(page number not for citation purposes)
2003, authors received answers from 88 out of 172 pris-
ons [34].
In this survey, HCV prevalence estimates remained quite
stable: 6.9% in 2003 and 6.3% in 2000.
One survey [35] conducted in 2005 and including 8 pris-
ons in Paris and its suburbs showed that among prisoners
at time of incarceration who reported having had already
been tested for HIV (41%) for HCV (38%) and for HBV
(37%), 0.6% reported to be HIV-positive, 5.9% HCV-pos-
itive and 3.4% HBV-positive. An important heterogeneity
existed among prisons concerning the rates of inmates
reporting to have had already been tested (from 29% to
80% for HIV, 17% to 80% for HCV and 27% to 80% for
HBV).
Drug and alcohol use at entry
Information on drug or alcohol use at entry is based on
self reported data. No data from urine or blood drug
screen were available.
At entry, 33.3% (1997) and 30.9% (2003) of inmates
reported excessive alcohol use (>4 alcohol units/day for
men and >2 alcohol units for women and/or > 4 consecu-
tive alcohol units at least once a month) [33].
Sahajian et al. [36] described the population of prisoners
at time of incarceration in prisons in the area of Lyon
between January 1st  and December 31st  2003. Among
them, 68.5% reported no regular employment in the pre-
vious 12 months and 52.8% had previously been impris-
oned. More than 64.0% of inmates reported regular
tobacco use, 16.5% cannabis use, 16.1% alcohol use, 25%
psychotropic medication, and 4.1% reported drug use
(heroine, cocaine or synthetic drugs). Moreover, 42.0% of
drug users reported polydrug use or dependence on 2 or
more drugs (see table 2).
Lukasiewicz et al. [37] randomly selected 998 prisoners.
Diagnoses were assessed using a structured interview
(MINI 5 plus) [38]. They identified overall 35.2% of
inmates as presenting either alcohol abuse and depend-
ence (18.4%) or drug abuse and dependence (27.9%)
with 11.2% (N = 111) presenting both conditions.
In the OPPIDUM project [39], a comparison was made in
the 2005 study between subjects with a history of drug use
in prison (215 subjects in 9 prisons) and primary care
(248 subjects). Among the former, 65% had used more
than one drug in the week preceding prison entry with a
mean of 2.3 drugs (45% in primary care with a mean of
1.6 drugs). Ten percent reported drug injection in the
week preceding prison entry (7% in the week before for
those in primary care), 29% had sniffed (13% in primary
care), 31% were alcohol dependant (6% in primary care),
48% had taken benzodiazepines (11% in primary care)
and 4% had injected buprenorphine (7% in primary
care).
Substitution treatments and psychotropic drugs at entry
In 2005, between 75,000 and 87,250 individuals in
France were receiving buprenorphine and between 14,100
and 20,200 were receiving methadone. These 89,100 to
107,450 persons accounted for nearly 70% of the esti-
mated opioid dependent population in France at that
time [40].
At prison entry, 0.6% of inmates in 1997 and 1.5% in
2003 reported being on methadone treatment, while for
buprenorphine these figures were 6.3% in 1997 and 6.0%
in 2003 [33] (see table 2). While the proportion of
inmates reporting persistent and regular use of opiates at
admission decreased during this period (self-report,
14.4% in 1997 but 6.5% in 2003), access to substitution
treatment appears to have improved (6.9% in 1997 vs.
7.5% in 2003). Inmates reported taking more anti-psy-
chotics and anti-depressants at prison entry in 2003 than
in 1997 (respectively 4.5% and 5.1% vs. 3.5% and 4.0%),
but less anxiolytics or hypnotics (12.0% vs. 15.2% in
1997) [33]. In the Sahajian et al. study [36] conducted in
2003, 11% of the 1,463 prisoners at incarceration for
whom information was available, had received OST
before prison entry.
In the 2005 Oppidum study [39], 56% of drug users who
answered the questionnaire had received OST (of which
78% were being treated with buprenorphine and 22%
with methadone) in the week prior to prison entry. This
figure was 85% in primary care (of which 71% were on
buprenorphine and 29% on methadone).
Drug injection in prison
Data regarding injection risk behavior in French prisons
are limited. Rotily [41] carried out a survey in four prisons
in the south and west of France. The survey was carried out
in response to a request from the Ministry of Health and
the Director of the correctional administration in 1997–
1998. An anonymous questionnaire including questions
on socio-demographic data, past sentences, drug use and
sexual behaviors prior to and during incarceration, tattoo-
ing, access to medical care and past medical history was
provided to all inmates. Overall, 72% of inmates agreed to
participate by answering the questionnaire (1,212 sub-
jects/1,695).
One hundred and fifty (13%) inmates reported having
injected drugs at least once during their lifetime, of whom
103 (77%) reported being active injecting drug users
(IDUs) during the previous 12 months. Forty five (30%)Harm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
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reported sharing needles or syringes during their last drug
injecting episode.
Inside prison, 43 (42%) of the 103 inmates who were
active IDUs before prison continued to inject in prison. Of
these 21% (9) reported sharing needles or syringes during
their most recent drug injecting episode. Seven inmates
(7% of the 103 active IDUs before prison) reported hav-
ing started injection practices in prison.
In a 2003 survey studying organization of OST provision
in 22 French prisons [42], in more than half prisons (12/
22), the prison staff (especially nurses) was aware of injec-
tion practices among prisoners.
In 2004 a national representative cross-sectional study of
injecting drug users [43] found that 60% of the 1,462 drug
users enrolled (i.e. those who reported sniffing or inject-
ing at least once during lifetime) reported one or more
experiences of incarceration. Among them, 12% reported
injection drug use during their prison stay, of whom 30%
reported having shared syringes or needles in prison.
Other risk behavior reported by inmates
In the Rotily et al. study [41], 1% of the 1,212 male and
female inmates who answered the questionnaire reported
homosexual sex in prison, while 8% reported heterosex-
ual sex. One percent reported accepting money for sex.
Only 20% of the inmates who reported homosexual sex in
prison reported condom use.
Table 2: Substance use and access to care at prison entry.
Mouquet Sahajian Lukasiewicz Oppidum Feuillerat
1997 (%) 2003 (%) 2003 (%) 2003–2004 (%) 2005 (%) 1998 (%) 2001 (%) 2004 (%)
Method :
Number of 
prisons, 
inmates
135 prisons 134 prisons 3 prisons 23 prisons 9 prisons All prisons
8 728 files 6 087 files 1 463 files 998 inmates 215 
questionnaires
Questionnaires to medical staff
Population Incoming 
inmates,
Incoming inmates, Incoming inmates Cross sectional 
study Stratified 
random sample
Drug users' 
sample self-
questionnaire
All inmates
Study period 1 month from 2 weeks to 
3 months 
depending of the 
size of the prison
1 year 1 week
diagnosis Regular, 
extended drug 
use previous 12 
months
Regular, extended 
drug use previous 
12 months
Regular use, 
abuse or 
dependence 
during previous 6 
months
DSM-IV criteria 
for drug abuse or 
dependence, 
including cannabis
1. Heroin, 
morphine, 
opium use
14.4 6.5 15
2. Cocaine/
crack use
8.9 7.7 4.1 [1+2+3] 27.9 [1+2+3+ 
cannabis use]
26
3. Other drugs 
(LSD, ecstasy)
3.4 4.0
4. Psychotropic 
drugs use
9.1 5.4 2.5 67
5. Polydrug use 14.6 10.5 29 65
6. Intravenous 
drug use
6.2 2.6 10
7. History of 
drug injection
11.8 6.5
8. Methadone 
at prison entry
0.6 1.5 22
9. 
Buprenorphine 
at prison entry
6.3 6.0 78
10. OST at 
prison entry* 
or during 
prison stay**
6.9* 7.5* 11* 56* 2.0** 5.4** 6.6**Harm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
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Almost a fifth (19%) reported being tattooed during their
prison stay with significantly more IDUs (39%) reporting
tattooing than non IDUs (18%).
Suicide
Suicides dramatically increased in French prisons between
1990 and 2000 (12.3 suicides/10 000 inmates vs. 23.9/10
000 inmates)[44].
Data regarding suicide among inmates sentenced for drug
offences are limited.
Of the 226 suicides among inmates in French prisons in
2001–2002, 15 involved inmates sentenced for drug
offences (suicidal rate = 11.1/10 000 inmates). This is a
lower rate than the mean inmate suicide rate (23.3/10 000
inmates) or the suicide rate for inmates incarcerated for
criminal offences (77.2/10 000 for murderers, 46.1/10
000 for rapists)[45].
Data for overdoses inside prisons are not available but are
also sparsely reported in the international literature.
Post release follow-up
A study conducted in 2001 [46] evaluated the mortality
rate of inmates in the first five years following release from
a large prison in a suburb of Paris. Among 1,439 inmates
released from January 1st to December 31, 1997, informa-
tion concerning mortality status was ascertained for only
1,245 inmates (86.5%). Seventy-one died between in
1997 and 2001, 35 of these (all men) during the first year
after their release. Data from 14 of these inmates who had
been transferred to this prison from other prisons for
medical reasons (a penitentiary hospital being available)
were excluded to avoid a selection bias. Twenty one
inmates therefore who died during the first year after
release (annual mortality rate = 1.8%) were included.
Causes of death were known only for those who died in
1997 and 1998. Causes of death included overdoses (N =
4), alcoholic cirrhosis (N = 3), cardiovascular diseases (N
= 3), suicides (N = 2), AIDS (N = 1), cancer (N = 1), respi-
ratory disease (N = 1) and unknown causes (N = 6).
The Standard Mortality Ratio (SMR) for inmates to gen-
eral population found a higher death rate for the released
inmates (SMR = 321.3) [46] confirming the results
reported in similar studies [47-50].
For inmates aged 15–34 years, the risk of drug overdose
death was 120 fold greater than the general population
while for inmates aged 35–54 years, the risk of drug over-
dose death was 270 times greater. Surprisingly, no drug
overdose deaths were recorded during the first 2 weeks
following prison release.
Recidivism rate
According to the Ministry of Justice [51], in 2004, 33.8%
(7 969) of the 23,550 subjects sentenced for drug related
offences had been previously incarcerated, and 11.2% (2
645) had previously been incarcerated for drug related
offences.
In the Regional Centre for Disease Control of South-East-
ern France (ORS-PACA) study [41], 28% of the 150 IDU
inmates reported at least 5 previous incarcerations and
49% had already spent more than 3 years in prison since
1980. Among the 978 non-IDU inmates, only 9% had
previously experienced 5 or more incarcerations with 35%
having spent more than 3 years in prison since 1980.
Screening, prevention and health promotion
HIV prevention in prisons is regulated by a 1996 Ministry
of Health/Ministry of Justice joint circular [52] and
includes education, HIV and hepatitis screening, anti-ret-
roviral post-exposure prophylaxis, access to HAART and
hepatitis C treatments, bleach distribution, condom dis-
tribution, opioid substitution treatment (OST) and organ-
ization of follow-up after release. Unlike a number of
other European countries, NSPs are still not permitted in
French prisons.
According to the official harm reduction joint report from
Ministry of Health and Ministry of Justice [53], the availa-
bility of education and staff training varies greatly from
one prison to another.
By contrast, in the same report [53], HIV and hepatitis
screening was considered to be satisfactory at prison entry
and during detention although it was recommended to
renew information and testing proposals more systemati-
cally and to improve the communication of results to
inmates as there were still excessive delays between tests
and results or inadequate communication of positive
results.
No data could be found concerning HIV incidence among
inmates or HIV outbreaks in French prisons.
Access to HAART
HAART is available in all French prisons. Nevertheless, a
national report from Ministry of health and Ministry of
Justice [44] found that during 1994–2000, fewer HIV pos-
itive individuals were receiving anti-retroviral treatment
in prison than in the general HIV-infected hospital popu-
lation (73% vs. 88% in 2000), monotherapy was more
common (20% vs. 12%) and multiple combination ther-
apy less common (9% vs. 17%). However, these differ-
ences disappeared after adjustment for AIDS severity level
(patients treated in reference HIV treatment centers hav-
ing more advanced disease than prison inmates), suggest-Harm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
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ing comparable access to HAART inside and outside
prison.
Bleach distribution
Bleach is distributed to inmates every 2 weeks and can be
purchased by inmates in prison inexpensively. According
to the ORS-PACA study [54], only 59% of the active inject-
ing drug inmates use bleach to disinfect their needles and
syringes. The joint health-justice report on harm reduc-
tion [53] in French prisons concluded that the protocol
needed to ensure the efficacy of bleach should be made
more accessible to inmates although a recent report by
WHO emphasized the lack of field evidence that bleach is
effective in preventing HIV transmission among injecting
drug users [55].
Condom distribution
Condoms should be available in all medical units inside
prisons and also be accessible in all other sites of the
prison environment. Among the 25 prisons evaluated in
the ORS-PACA study (1998)[54], condoms were only
available in 23. In addition, 34% of inmates believed that
condoms were not available in prisons, and 29% reported
that they needed to ask doctors or nurses to obtain them.
Substitution therapy
Methadone and buprenorphine have been widely used in
France since 1996 as OST. In 2005, between 75,000 and
87,250 individuals in France were receiving buprenor-
phine and between 14,100 and 20,200 methadone [40].
Since 1996, both agents have been made available in
French prisons for patients whose treatment was previ-
ously initiated outside prison. Until 2002, only buprenor-
phine could be initiated inside prisons except when
authorized physicians (prescribing doctors in methadone
programs) had been consulted by the patient. Since 2002,
all hospital doctors (including doctors working in prison)
have been authorized to initiate methadone in prisons.
The national report from the Ministry of Health and the
Ministry of Justice [44], concluded that OST coverage in
French prisons had been only increasing slowly in recent
years because many doctors were not only reluctant to ini-
tiate OST in prison but were also to simply renew existing
buprenorphine or methadone prescription. The propor-
tion of inmates receiving OST increased from 2% in 1998
to 3.3% in 1999, 5.4% in 2001 and 6.6% in 2004 [56].
These proportions are comparable to those observed out-
side prisons if we take into account the estimated preva-
lence of drug use among inmates at prison entry 23% to
43% [57]. A study carried out in 2002–2003 [42] docu-
mented OST coverage in 22 prisons (accounting for
11,168 inmates, 20% of all French inmates at the time of
the study). Most of the inmates were on remand and over-
all 7.8% (N = 870) were receiving OST, 81.5% with high
dosage buprenorphine (N = 709) and 18.5% (N = 161)
with methadone. Important variations in access to OST
were observed between prisons with inmates on OST in
small prisons accounting for only 2% of the total com-
pared to 16% from larger prisons. Care provision and
management including access to HAART and OST varied
considerably between French prisons. Medical and prison
staff expressed a preference for methadone, as daily deliv-
ery was easier to control and consequently resulted in less
trafficking. Buprenorphine diversion (by injection or
sniffing) and consequent trafficking was a major concern
for prisons and medical staff. Inmates reported inade-
quate confidentiality and major stigmatization associated
with daily delivery of OST.
In 2006, a national survey [58] was carried out to evaluate
the impact of access to methadone initialization in all
hospital outpatient services including prison medical
services. The percentage of methadone patients among
inmates receiving OST increased to 35% in 2006 from
22% in 2004; among patients receiving methadone, 60%
initiated methadone treatment inside prison in 2006
(89.7% for buprenorphine initiation). Of the 98 prisons
in total answering the questionnaire, physicians refused to
initiate methadone prescription for "ethical" reasons in 3
prisons and for practical or organizational reasons in 8
others. In addition, in 12 prisons, the absence of metha-
done initiation was justified by the absence of indication.
Among the total number of prescriptions of methadone
inside prisons, 28% concerned initiation of methadone
prescription.
Discussion
These data indicate that the proportion of individuals
incarcerated in France for drug-related offences is rela-
tively high. Two thirds of sentences imposed for drug-
related offences involve individuals arrested for illicit use
of drugs or possession or acquisition of illicit drugs.
Although the duration of incarceration for these drug-
dependent individuals may be relatively short, it seems
likely that any delay in initiating OST for these individuals
increases the chance of high risk injecting practices in
prison. This was confirmed in two studies, one carried out
in 2000 in prison [41] and the other in 2004 in the general
community [43].
The first study clearly showed that approximately half
(42%) of those reporting active drug use prior to incarcer-
ation continued to inject in prison, of whom 21%
reported sharing needles or syringes in prison [41]. This
result is consistent with findings in a more recent national
representative survey enrolling drug users at different
entry points (NSP, methadone buses, centers for drug
users etc) which showed that, among those who practicedHarm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
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injection in prison, one third reported having shared
syringes and needles in prison [43].
There are great difficulties in estimating the prevalence of
injecting practices in prisons. This is partly due to the lack
of recent data but also because of under-reporting. How-
ever, it seems that although injecting practices are less
prevalent among prison inmates in France than among
their counterparts in other countries [59], a considerable
portion of inmates are still at high risk of blood-borne
viral infections.
In addition, considering that the prevalence of HIV in
these populations is around 11%, HIV-infected individu-
als at prison entry do experience at least 2 day interrup-
tions of their HAART, especially if prison entry occurs
during the week-end.
It is widely known that these interruptions considerably
increase the risk of developing resistance [60,61] with a
consequently high probability of circulation of HIV resist-
ant strains in prison settings.
The continuity of HIV care for inmates remains a major
problem which is strongly related to the risk of stigmati-
zation in prison and the problem of social integration
after release.
It has major public health implications, and is becoming
reported more frequently [62,63], especially since the
introduction of HAART regimens which are "less forgiv-
ing" (i.e. requiring higher adherence to obtain viro-immu-
nological response) and which can increase the risk of
virological failure [63] or resistance in re-incarcerated
individuals due to reduced adherence or treatment inter-
ruptions after release. HIV care needs to commence within
the first day of incarceration and post-incarceration care
needs to be arranged before release.
Compared with other European countries [59] in a cross-
sectional European survey, HIV prevalence in French pris-
ons (2.2%) was situated just between that found in south-
European countries (6.2% in Italia, 16.7% in Portugal,
12.9% in Spain) and in north-European countries (0.7%
in Germany, 1.6% in Sweden, 1% in Scotland, 0% in Bel-
gium). The same result existed for HCV (8.3%) between
south-European countries (24% in Italy, 34.1% in Portu-
gal, 46.7% in Spain) and north-European countries (4.9%
in Germany, 10.9% in Belgium).
The situation concerning OST access is slowly improving
but there is still an important heterogeneity of care
between prisons and insufficient coverage of inmate
needs [42]. According to the European Network of Drug
Services in Prison (ENDSP) report in 2004 [64], an impor-
tant heterogeneity also exists between European countries
and inside many European countries themselves. A treat-
ment gap persists between those requiring substitution
treatment and those receiving it and, in most of the coun-
tries studied, coverage is irregular. In 2004 Greece and
Sweden still did not offer treatment in prisons. In most
countries, treatments are discontinued or dosages reduced
when someone enters prison. In some countries, OST are
limited to a period of between 6 to 12 months.
Its role in facilitating delivery of antiretroviral therapy to
IDUs should be given greater recognition in prisons [65].
Despite the availability of OST in French prisons, the lack
of access to NSP means that inmates who are still injecting
while incarcerated are at high risk of HCV or HIV serocon-
version. The introduction of NSP in prison is urgent and
is also justified by recent data [66] showing that access to
both methadone and NSP has an impact on HCV serocon-
version. However, despite WHO support for the strong
evidence base for prison NSPs [55], little headway has
been achieved in France in the debate about their intro-
duction. This may be due to the following reasons: firstly,
as some inmates are incarcerated only because of their
illegal drug consumption, allowing access to NSPs inside
prison would highlight the limited effectiveness of incar-
ceration in the promotion of abstinence and would also
draw attention to the inadequacy of a drug policy heavily
reliant on supply control. This could prompt many com-
munity members to consider alternatives to a policy dom-
inated by drug law enforcement. Secondly, NSPs are still
regarded by the correctional staff and authorities as
"weapons in inmates' hands".
This is quite surprising if we consider that access to NSPs
is readily available in community settings in France and
that such access has greatly contributed to the reduction of
HIV prevalence among IDUs [28]. NSPs are already avail-
able in Switzerland, Germany, Spain, Luxembourg and
Scotland, and will soon become available in Portugal and
in a growing number of developing countries [55].
Data about HIV, HCV and HBV prevalence at prison entry
are difficult to interpret because they are either based on
self-report or on testing of those who agreed to be tested
(and therefore may bias estimates of prevalence). The
higher proportion of individuals tested for HCV is attrib-
utable to more active testing, due to the availability of
HCV treatment in prisons. Interestingly, a three-fold
increase in the proportion of individuals vaccinated
against HBV was observed between 1997 and 2003, but it
is not yet known to what extent this reflects changes in the
general population of people at risk of HBV seroconver-
sion or is due to a change in the characteristics of individ-
uals entering prison.Harm Reduction Journal 2008, 5:17 http://www.harmreductionjournal.com/content/5/1/17
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Assessment of alcohol dependence at prison entry is insuf-
ficiently emphasized at present as one third of inmates
report excessive alcohol consumption, only sometimes
associated with drug dependence. However the propor-
tion of individuals who are recent IDUs at prison entry
seems to have decreased over the past years, probably
reflecting wider access to OST but also a change from
injecting to less harmful routes of administration (such as
sniffing or snorting) in the community. Mortality after
release, mostly due to drug overdoses, is high and compa-
rable in France to results found in similar studies for other
countries [67]. The post prison release period is usually
considered a very risky time for overdose as already shown
in other studies [68].
The increasing use of psychotropic drugs among prison
entrants suggests the importance of providing compre-
hensive care in prison settings with psychiatrists and psy-
chologists possibly playing a major role in the
identification and management of psychiatric co-morbid-
ities and alcohol and drug dependence but also in HIV or
HCV treatment related side effects.
The existence of unsafe sexual behaviors during incarcera-
tion and undervalued importance of the high prevalence
of tattooing suggests the need for additional preventive
measures [69].
The high recidivism rate of IDUs and consequent rapid
cycling in and out of prison almost certainly contribute
greatly to the transmission of blood-borne infections
(including viral resistant strains) from prison to the gen-
eral population.
Moreover, access to care is still inadequate and services
increasingly stretched by an ever growing prison popula-
tion and the high prevalence of co-existing severe mental
and other health and social problems which exacerbate
the difficulties in providing a comprehensive health
approach in prison settings [37,70]
Some recommendations can be outlined from these data.
Access to OST in prison requires improvement in moni-
toring standardized approaches to ensure equity of access
in prison. Similarly, condom distribution should be
expanded to all areas of prisons to ensure confidentiality
and avoid stigma. In addition, access to post-exposure
prophylaxis in the event of sexual or parenteral exposure
should be promoted to ensure access is comparable to
that for the general population. Health authorities need to
become more sensitive to the problems of HAART inter-
ruption as these may not only induce failures of HIV treat-
ment in inmates but may also contribute to the circulation
of HIV resistant strains both inside and outside prisons.
Effective, evidence-based preventive measures in prison
settings may reduce harm resulting from multiple incar-
cerations or long periods of imprisonment.
Conclusion
The large gap in France between health prevention and
treatment services in the community and the equivalent
services for prison inmates cannot be defended.
This set of indicators, though limited and often outdated,
clearly highlights the need for more research in this field
in order to both obtain accurate estimates of HIV-HCV
occurrence and risk behaviors in French prisons, and carry
out interventional studies to identify which models can
assure continuity of care and appropriate social services
after release.
Irrational hostility to prison NSPs must be overcome by
authorities so that pilot studies can be commenced in a
few prisons to demonstrate their feasibility in the French
prison system.
Introducing preventive and harm reduction measures not
yet available in French prisons is not only a human right
for prison inmates but can also provide important public
health benefits for the general population.
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